Charles River Laboratories International, Inc.
CRLHealthcareNASDAQDiagnostics & Research · Last scanned May 30, 2026
Scan Results
Daily timeframeCharles River Laboratories International, Inc. operates in the Diagnostics & Research space. Charles River Laboratories International, Inc. Valued at $8.70B, CRL is a mid-cap name in its sector. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.
Market Cap
$8.70B
Beta
1.45
P/E (TTM)
—
P/E (Fwd)
14.68
EPS (TTM)
$-3.70
EPS (Fwd)
$12.31
ROE
-5.9%
ROA
4.3%
Cash
$191.8M
Total Debt
$3.06B
Free CF
$510.0M
52W Change
33.8%
Annual Financials
Cash vs Debt
The company holds $191.8M in cash, though total debt stands at $3.06B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $510.0M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -5.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.3% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $3.54B to $4.02B.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CRL.